CUVPOSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CUVPOSA (CUVPOSA).
Cuvposa (glycopyrrolate) is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3). It reduces salivary secretions by blocking parasympathetic nerve impulses in salivary glands, thereby decreasing the volume and frequency of drooling.
| Metabolism | Glycopyrrolate is minimally metabolized, primarily by the liver via ester hydrolysis and conjugation. It is not significantly metabolized by CYP450 enzymes. |
| Excretion | CUVPOSA (glycopyrrolate) is primarily eliminated unchanged in the urine (approximately 85% renal excretion of the absorbed dose) and feces (approximately 5% via biliary/fecal route). |
| Half-life | The terminal elimination half-life is approximately 0.6 to 1.2 hours after intravenous administration; in pediatric patients with neurologic conditions, the half-life may be prolonged up to 1.5 to 2.5 hours. This short half-life necessitates frequent dosing for sustained anticholinergic effects. |
| Protein binding | Glycopyrrolate is moderately protein bound (approximately 45% to 50%), primarily to albumin. |
| Volume of Distribution | The volume of distribution is approximately 0.4 to 0.6 L/kg, suggesting limited extravascular distribution and mainly remaining in the central compartment. |
| Bioavailability | Oral bioavailability is low and variable, approximately 1% to 5% due to poor absorption and extensive first-pass metabolism. |
| Onset of Action | After oral administration, the onset of action for reduction of drooling is typically within 1 to 2 hours. |
| Duration of Action | The duration of action for reduction of drooling is approximately 5 to 6 hours after a single oral dose, supporting three-times-daily dosing. Note: Individual response may vary. |
| Molecular Weight | 362.46 |
1 mg/mL oral solution: initial dose 0.02 mg/kg orally 3 times daily; titrate upward by 0.004 mg/kg per dose every 5–7 days to optimal effect; maximum single dose 0.1 mg/kg (not to exceed 1.5 mg per dose) or 0.2 mg/kg per dose (not to exceed 3 mg per dose) if benefit-risk justifies higher dose.
| Dosage form | SOLUTION |
| Renal impairment | No specific guidelines; use with caution in renal impairment. For severe renal impairment (eGFR <30 mL/min), consider dose reduction by 25-50% due to potential increased systemic exposure. |
| Liver impairment | No specific guidelines; use with caution in hepatic impairment. For moderate to severe hepatic impairment (Child-Pugh class B or C), consider dose reduction by 50% due to decreased metabolism. |
| Pediatric use | Administer as for adults: initial 0.02 mg/kg orally 3 times daily; titrate by 0.004 mg/kg per dose every 5–7 days; maximum single dose 0.1 mg/kg (not to exceed 1.5 mg) or up to 0.2 mg/kg (not to exceed 3 mg) if tolerated. |
| Geriatric use | Start at low end of dosing range (0.02 mg/kg) and titrate cautiously; monitor for anticholinergic adverse effects (e.g., constipation, confusion, urinary retention). Consider lower maintenance doses due to age-related decline in clearance. |
| 1st trimester | Limited human data; animal studies show fetal abnormalities. Use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal anticholinergic effects. Caution advised. |
| 3rd trimester | May cause neonatal anticholinergic symptoms (e.g., ileus, respiratory depression). Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for CUVPOSA (CUVPOSA).
| Placental transfer | Crosses placenta; degree unknown in humans, but anticholinergic drugs generally cross. |
| Breastfeeding | Excreted in breast milk in low amounts; monitor infant for anticholinergic effects (e.g., irritability, GI disturbance). Use with caution. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to glycopyrrolate or any componentGlaucomaObstructive uropathyGastrointestinal obstructionParalytic ileusSevere ulcerative colitisMyasthenia gravisToxic megacolon
| Precautions | Anticholinergic effects: May cause constipation, urinary retention, blurred vision, heat intolerance, and reduced sweating leading to hyperthermia., Use in patients with gastrointestinal obstruction, myasthenia gravis, or ulcerative colitis may worsen condition., Monitor for signs of anticholinergic toxicity (e.g., delirium, tachycardia)., Not recommended for use in patients with glaucoma or severe renal impairment. |
| Food/Dietary | No specific food interactions. High-fat meals may delay absorption but do not affect overall exposure. Avoid alcohol as it may exacerbate CNS depression. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, glycopyrrolate (the active ingredient in CUVPOSA) was teratogenic in rabbits at doses approximately 0.7 times the maximum human dose. Fetal risks are unknown in humans; use only if potential benefit justifies potential risk to the fetus. First trimester: risk cannot be ruled out. Second and third trimesters: limited data, but theoretical risk of anticholinergic effects (e.g., fetal tachycardia, meconium ileus). |
| Fetal Monitoring | Monitor fetal heart rate during labor and delivery due to potential anticholinergic effects (tachycardia). In pregnancy, monitor for maternal anticholinergic adverse effects (constipation, urinary retention, blurred vision). No specific fetal monitoring required outside standard obstetric care. |
| Fertility Effects | No human data on fertility effects. In animal studies, reduced sperm motility and fertility were observed at high doses. May potentially impair male and female fertility based on anticholinergic effects on reproductive function. |
| Clinical Pearls | CUVPOSA (glycopyrrolate) oral solution is indicated for chronic severe drooling in children aged 3-16 years with neurologic conditions. Onset of action is 1-2 hours; titrate dose slowly to minimize anticholinergic side effects. Monitor for constipation, urinary retention, and heat intolerance. Avoid use in patients with glaucoma, myasthenia gravis, or gastrointestinal obstruction. |
| Patient Advice | Take CUVPOSA exactly as prescribed, usually three times daily, with or without food. · Do not crush or chew the liquid; use the provided dosing syringe for accurate measurement. · May cause dry mouth, constipation, blurred vision, or difficulty urinating; report severe symptoms. · Avoid overheating and strenuous exercise due to decreased sweating risk. · Keep out of reach of children; store at room temperature, do not freeze. |